MONTREAL, May 09, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) announced today the voting results from the Annual Meeting of the Shareholders held in Montreal, Quebec (“Meeting”).

Election of Directors

Each director nominee listed in the Management Information Circular dated March 30, 2018 (“Circular”) was elected as Director of the Corporation at the Meeting. Shareholders present in person or represented by proxy at the Meeting voted as follows:

DIRECTOR Nominee Outcome Votes For % For votes Withheld % Withheld
James C. Gale Elected 105,326,121 98.26 % 1,865,457 1.74 %
Jonathan Ross Goodman Elected 105,489,157 98.41 % 1,702,421 1.59 %
Samira Sakhia Elected 102,558,068 95.68 % 4,633,510 4.32 %
Robert N. Lande Elected 106,615,046 99.46 % 576,532 0.54 %
Sylvie Tendler Elected 106,593,510 99.44 % 598,068 0.56 %
Meir Jakobsohn Elected 104,127,029 97.14 % 3,064,549 2.86 %
Sarit Assouline Elected 101,213,051 94.42 % 5,978,527 5.58 %

Appointment of external Auditors

Ernst & Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present or represented by proxy, and the directors were authorized to determine their remuneration. Shareholders present in person or represented by proxy at the Meeting voted as follows:

Appointed 107,364,861 98.37 % 1,782,631 1.63 %

The results of the final votes regarding all matters subject to a vote during the Meeting will also be made available on SEDAR ( 

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at or

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2017. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. 

For further information please contact:

Knight Therapeutics Inc.
Samira Sakhia
President and Chief Financial Officer
T: 514-678-8930
F: 514-481-4116


Primary Logo